Identifying factors that help clear toxic protein aggregates in neurodegenerative diseases
Uncovering cell factors with aggregate clearance activity by scalable induced proximity
['FUNDING_OTHER'] · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · NIH-11246042
This study is looking at how specific proteins and RNAs can help get rid of harmful clumps in the brain that are linked to Alzheimer's and frontotemporal dementia, with the hope of finding new treatments to improve care for people with these conditions.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUTGERS BIOMEDICAL AND HEALTH SCIENCES (nih funded) |
| Locations | 1 site (Newark, UNITED STATES) |
| Trial ID | NIH-11246042 on ClinicalTrials.gov |
What this research studies
This research investigates how certain proteins and RNAs can help clear toxic aggregates that form in neurodegenerative diseases like Alzheimer's and frontotemporal dementia. By using a method called ligand-induced proximity, the study aims to identify components of the proteostasis network that can effectively remove these harmful aggregates. The research involves systematic screening of various proteins and RNAs to discover new mechanisms that could lead to potential therapies for these conditions. If successful, this work could pave the way for developing new drugs that target these aggregates.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or frontotemporal dementia, particularly those experiencing symptoms related to protein aggregation.
Not a fit: Patients with neurodegenerative diseases not associated with protein aggregation or those in very advanced stages of these diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating neurodegenerative diseases by enhancing the clearance of toxic protein aggregates.
How similar studies have performed: Previous research using similar approaches with small molecule ligands has shown promise in clearing aberrant protein species, suggesting potential for success in this study.
Where this research is happening
Newark, UNITED STATES
- RUTGERS BIOMEDICAL AND HEALTH SCIENCES — Newark, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SEREBRENIK, YEVGENIY VLADIMIROVICH — RUTGERS BIOMEDICAL AND HEALTH SCIENCES
- Study coordinator: SEREBRENIK, YEVGENIY VLADIMIROVICH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: age associated neurodegenerative disease, age associated neurodegenerative disorder